Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 270-273

  Kobayashi, Ryoji ^a   Sato, Tomonobu ^a   Nakajima, Masahide ^b   Kaneda, Makoto ^c   Iguchi, Akihiro ^d  

^a SAPPORO HOKUYU HOSPITAL   (Japan)

^b ASAHIKAWA CITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Aztreonam; Ceftazidime; Febrile neutropenia; Piperacillin tazobactam; Sulbactam ampicillin

Indexed keywords

AZTREONAM; CEFTAZIDIME; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT; SULBACTAM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; FEVER; HOSPITALIZATION; NEOPLASM; NEUTROPENIA; NEWBORN; PROSPECTIVE STUDY;

ADOLESCENT; AMPICILLIN; ANTI-BACTERIAL AGENTS; AZTREONAM; BETA-LACTAMS; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULBACTAM;

EID: 65349187743     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31819daf4a     Document Type: Article

References (32)

1. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
2. Viscoli C, Moroni C, Boni L, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis. 1991;13:397-404.
3. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445-452.
4. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991;163:951-958 .
5. Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematologi-cal malignancies. J Antimicrob Chemother. 1992;30:843-854.
6. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552-558.
7. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995; 13:165-176.
8. De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994;120:834-844.
9. Daley D, Mulgrave L, Munro R, et al. An evaluation of the in vitro activity of piperacillin/tazobactam. Pathology. 1996;28: 167-172.
10. Verbist L, Verhaegen J, Wouters C, et al. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group. J Antimicrob Chemother. 1996;37:285-293.
11. Neu HC. Aztreonam activity, pharmacology, and clinical uses. Am J Med. 1990;88(suppl 3C):2-6.
12. Parry MF. Aztreonam susceptibility testing. A retrospective analysis. Am J Med. 1990;88(suppl 3C):7-11.
13. Rolston KV, Bodey GP, Elting L. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients. Am J Med. 1990;88(suppl 3C):24-29.
14. Lebel MH, McCracken GH Jr. Aztreonam: review of the clinical experience and potential uses in pediatrics. Pediatr Infect Dis J. 1988;7:331-339.
15. Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am J Med. 1990;88(suppl 3C):12-15.
16. Ariffin H, Ai CL, Lee CL, et al. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health. 2006;42:781-784.
17. Hamidah A, Lim YS, Zulkifli SZ, et al. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J. 2007;48: 615-619.
18. Corapçioglu F, Sarper N. Cefepime versus ceftazidime+ amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005; 22:59-70.
19. Chuang YY, Hung IJ, Yang CP, et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutro-penia in children with cancer. Pediatr Infect Dis J. 2002;21: 203-209.
20. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001;20:362-369.
21. Oguz A, Karadeniz C, Citak EC, et al. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol. 2006;23:245-253.
22. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841-853.
23. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177-186.
24. Takeuchi M, Tanizawa A, Mayumi M. Piperacillin plus aztreonam for treatment of neutropenic fever. Pediatr Int. 2003;45:307-310.
25. Le Guyader N, Auvrignon A, Vu-Thien H, et al. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer. 2004;12:720-724.
26. Kebudi R, Görgün O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001;36:434-441.
27. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
28. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13:281-287.
29. Mullen CA, Petropoulos D, Roberts WM, et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. Pediatr Hematol Oncol. 1999;21:212-218.
30. Rosenman M, Madsen K, Hui S, et al. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol. 2002;24:263-268.
31. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics. 1994;6:233-239.
32. Dranitsaris G, Tran TM, McGeer A, et al. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics. 1995;7:49-62.